ConductScience.org, home

Comparison · NCT00282984-de607912

Varenicline (Var) vs Placebo (Pbo): Number of Participants With a 4 Week Point Prevalence of Smoking Cessation

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Varenicline (Var) vs Placebo (Pbo): Number of Participants With a 4 Week Point Prevalence of Smoking Cessation. Trial comparisons, record NCT00282984-de607912. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00282984-de607912

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.280.2360.329wilson
Risk in group 20.1630.1280.205wilson
Risk difference, group 1 minus group 20.1180.05630.178newcombe hybrid score
Risk ratio, group 1 over group 21.721.292.3log
Odds ratio, group 1 over group 221.392.89log
Number needed to treat, for one more participant with the outcome on Varenicline (Var) than on Placebo (Pbo)8.55.6217.8from the risk difference interval

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Varenicline (Var)
1 week titration followed by 11 weeks of 1 milligram (mg) twice daily (BID) dosing. Study medication was discontinued at the Week 12 visit and participants' smoking status was followed through the non-treatment period to Week 52.
99353OG000
Group 2Placebo (Pbo)
1 week titration followed by 11 weeks of placebo (pbo). Study medication was discontinued at the Week 12 visit and participants' smoking status was followed through the non-treatment period to Week 52.
57350OG001

Outcome

Type
SECONDARY
Title
Number of Participants With a 4 Week Point Prevalence of Smoking Cessation
Description
Responders: participants with abstinence during the last 4 weeks of non-treatment based on answering 'no' to both of the two 'last 4 week' questions in the Nicotine Use Inventory (NUI). NUI collected information of cigarette or other nicotine use during the study.
Time frame
Week 48 through Week 52 (final 4 weeks of non-treatment period [pd])
Population
All Participants population

Source ClinicalTrials.gov

Trial

Title
Efficacy and Safety of Varenicline in Smokers With Cardiovascular Disease Who Wish to Quit Smoking
NCT number
NCT00282984
Phases
PHASE3
Conditions
Smoking Cessation
Interventions
placebo, Varenicline
Lead sponsor
Pfizer
Results first posted
2009-04-29

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT00282984-de607912